Skip to main
  1. Stocks
  2. Glaukos
  3. Forecast
GKOS

Glaukos (GKOS) Stock Forecast & Price Target

Glaukos (GKOS) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 58%
Buy 33%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Glaukos is viewed positively because its preliminary FY27 revenue guide of about $1B materially exceeds prior consensus of $852.4M, signaling that Epioxa, iDose, and the legacy MIGS franchise are all contributing to a faster-than-expected growth profile. The company’s 3Q26 results reinforce that thesis, with total revenue of $211.0M, gross margin near 85%, and positive non-GAAP earnings, while iDose generated about $76M and corneal health about $59M, showing two sizable growth engines. The investment case also benefits from improving commercialization access, with Epioxa supported across more than 90% of commercial lives and 80% of Medicaid lives, 700+ detection centers, and iDose still in early penetration, leaving room for further operating leverage and profit expansion.

Bears say

Glaukos is facing a fundamental risk profile driven by slower-than-expected MIGS market growth, which could limit demand for its core glaucoma devices and compress the company’s ability to scale revenue across its surgical portfolio. Its outlook is further pressured by uncertainty around adoption of iDose and infinite, along with the possibility of slower product launches than assumed, especially Epioxa in Corneal Health, which would delay commercialization benefits and weaken growth expectations. In addition, an expanding number of competitors and potential changes in the reimbursement landscape could intensify pricing pressure, reduce market share, and make execution more difficult across its ophthalmic platform.

Glaukos (GKOS) has been analyzed by 12 analysts, with a consensus rating of Buy. 58% of analysts recommend a Strong Buy, 33% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.

Glaukos (GKOS) Analyst Forecast & Price Prediction

Get the latest Glaukos (GKOS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Glaukos (GKOS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Glaukos (GKOS) Forecast

Analysts have given Glaukos (GKOS) a Buy based on their latest research and market trends.

According to 12 analysts, Glaukos (GKOS) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $225.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $225.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Glaukos (GKOS)


Glaukos (GKOS) Analyst Forecast & Price Prediction

Get the latest Glaukos (GKOS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Glaukos (GKOS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover GKOS stock data and trends